Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 23.31% | 24.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.31% | 24.23% | |||
| Cost of Revenue | 0.47% | 37.27% | |||
| Gross Profit | 28.15% | 21.78% | |||
| SG&A Expenses | -6.98% | 4.37% | |||
| Depreciation & Amortization | -- | -0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.86% | 13.34% | |||
| Operating Income | 235.43% | 19.24% | |||
| Income Before Tax | 126.80% | -13.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 126.80% | -13.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 126.80% | -13.80% | |||
| EBIT | 235.43% | 19.24% | |||
| EBITDA | 1,955.57% | 75.92% | |||
| EPS Basic | 124.93% | -9.44% | |||
| Normalized Basic EPS | 131.45% | 10.76% | |||
| EPS Diluted | 124.93% | -9.44% | |||
| Normalized Diluted EPS | 130.51% | 10.76% | |||
| Average Basic Shares Outstanding | 7.68% | 3.97% | |||
| Average Diluted Shares Outstanding | 10.47% | 3.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||